1
Miao Zenwei, Sun Ying, Wu Frank, Nakajima Suanne, Xu Guoyou, Or Yat Sun, Wang Zhe: Macrocyclic hepatitis c serine protease inhibitors. Enanta Pharmaceuticals, Miao Zenwei, Sun Ying, Wu Frank, Nakajima Suanne, Xu Guoyou, Or Yat Sun, Wang Zhe, HSI Jeffrey D, August 26, 2004: WO/2004/072243 (113 worldwide citation)

The present invention relates to compounds of Formula (I, II or III), or a pharmaceutically acceptable salt, ester, or prodrug, thereof: (I), (II), (III), wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity o ...


2
Sommadossi Jean Pierre, La, Colla Poalo, Storer Richard, Gosselin Gilles: Modified 2 and 3 -nucleoside produgs for treating flaviridae infections. Idenix, Centre National de La Recherche Scientifique, Universita Degli Studi Di Cagliari, Sommadossi Jean Pierre, La, Colla Poalo, Storer Richard, Gosselin Gilles, KNOWLES Sherry M, January 8, 2004: WO/2004/002999 (109 worldwide citation)

2' and/or 3' prodrugs of l', 2', 3' or 4'-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and composi ...


3

4

5
Sommadossi Jean Pierre, La, Colla Paolo, Storer Richard, Gosselin Gilles: 1’-, 2- and 3- modified nucleoside derivatives for treating flaviviridae infections. Idenix, Centre National de La Recherche Scientifique, Universita Degli Studi Di Cagliari, Sommadossi Jean Pierre, La, Colla Paolo, Storer Richard, Gosselin Gilles, KNOWLES Sherry M, January 8, 2004: WO/2004/003000 (89 worldwide citation)

2' and 3'-Prodrugs of l', 2', 3' or 4'-branched ß-D or ß-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior resu ...


6

7
DEGOEY DAVID A: Anti-viral compounds. Abbott Laboratories, Mueller Lisa, July 1, 2010: WO/2010/075376 (83 worldwide citation)

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.


8
Holloway M Katharine, Liverton Nigel J, Mccauley John A, Rudd Michael T, Vacca Joseph P, Ludmerer Steven W, Olsen David B: Macrocyclic peptides as hcv ns3 protease inhibitors. Merck & Co, Holloway M Katharine, Liverton Nigel J, Mccauley John A, Rudd Michael T, Vacca Joseph P, Ludmerer Steven W, Olsen David B, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, February 8, 2007: WO/2007/016441 (82 worldwide citation)

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. Formula (I).


9

10